Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 14;21(1):74.
doi: 10.1186/s12933-022-01516-6.

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Cheng-Xu Ma  1   2 , Xiao-Ni Ma  1   2 , Cong-Hui Guan  1   2 , Ying-Dong Li  3 , Dídac Mauricio  4 , Song-Bo Fu  5   6
Affiliations
Review

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

Cheng-Xu Ma et al. Cardiovasc Diabetol. .

Abstract

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.

Keywords: Antidiabetic therapy; Cardiovascular diseases; Hyperlipidemia; Hypertension; Therapy principle; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

I declare that the authors have no competing interests as defined by BMC, or other interests that might be perceived to influence the results and/or discussion reported in this paper.

References

    1. Diabetes. World Health Organization 2021, https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 10 Nov 2021.
    1. World health statistics 2020: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization 2020. Licence: CC BY-NC-SA 3.0 IGO.
    1. World health statistics 2021: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization 2021. Licence: CC BY-NC-SA 3.0 IGO.
    1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83–83. doi: 10.1186/s12933-018-0728-6. - DOI - PMC - PubMed
    1. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021 doi: 10.1038/s41580-021-00390-6. - DOI - PubMed

Publication types

MeSH terms